Video

Q&A with David Loren: Managing Patients With Pancreatic Cystic Lesions

Author(s):

The molecular test PancraGen helps identify false negative cases that could be missed by first-line tests like imaging, cytology and fluid chemistry.

David Loren, MD, Thomas Jefferson University, shares data on the molecular test PancraGen, which helps identify false negative cases that could be missed by first-line tests like imaging, cytology and fluid chemistry.

Loren commented, "We're trying to find those molecular markers. It's a completely different scientific approach to what we call the other types of what we call 'first-line' approach".

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.